Literature DB >> 2598177

Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products.

M Nelson1, D S Nelson, G J Cianciolo, R Snyderman.   

Abstract

CKS-17 is a heptadecapeptide corresponding to a region highly conserved in retroviral transmembrane proteins such as p15E. Because a relationship had previously been determined between p15E and immunosuppressive tumor cell products, we examined the effect of CKS-17, control peptides and conjugates thereof on the expression of cell-mediated immunity (delayed-type hypersensitivity, DTH) in mice. Conjugates of CKS-17 inhibited DTH reactions to sheep erythrocytes in the feet of mice. The degree of inhibition was dose-dependent. Unconjugated CKS-17 had almost no effect, and control peptide conjugates had no inhibitory effect. Immunization of mice with CKS-17 conjugates, but not with control conjugates, rendered them resistant to the depression of DTH reactions, not only by CKS-17 conjugates, but also by products of cultured tumor cells. CKS-17 conjugates, but not control conjugates, also depressed the cellular inflammatory reactions induced in mouse footpads by concanavalin A (ConA) and immunized mice against the depression of ConA reactions by products of cultured tumor cells. Injections of globulin from sera of mice immunized with CKS-17 conjugates conferred upon normal recipients resistance to the depression of footpad reactions to ConA by products of cultured tumor cells. Globulin from sera of normal mice or control immunized mice did not confer such resistance. Thus conjugates of a synthetic peptide not only mimic the immunosuppressive effects of tumor products in vivo, but can also immunize mice against those effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598177     DOI: 10.1007/bf01665962

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

1.  Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins.

Authors:  G J Cianciolo; T D Copeland; S Oroszlan; R Snyderman
Journal:  Science       Date:  1985-10-25       Impact factor: 47.728

2.  Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses.

Authors:  M Mitani; G J Cianciolo; R Snyderman; M Yasuda; R A Good; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

3.  Influence of dose and route of antigen injection on the immunological induction of T cells.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

Review 4.  Macrophage infiltration and tumor progression.

Authors:  S J Normann
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

5.  Delayed hypersensitivity in mice induced by intravenous sensitization with sheep erythrocytes: evidence for tuberculin type delayed hypersensitivity of the reaction.

Authors:  A Mitsuoka; T Teramatsu; M Baba; S Morikawa; K Yasuhira
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

6.  Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV.

Authors:  G J Cianciolo; R J Kipnis; R Snyderman
Journal:  Nature       Date:  1984 Oct 11-17       Impact factor: 49.962

7.  Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice.

Authors:  A Benomar; W J Ming; G Taraboletti; P Ghezzi; C Balotta; G J Cianciolo; R Snyderman; J F Doré; A Mantovani
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

8.  Macrophages and resistance to tumors. IV. Influence of age on susceptibility of mice to anti-inflammatory and antimacrophage effects of tumor cell products.

Authors:  M Nelson; D S Nelson
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

9.  Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses.

Authors:  G Cianciolo; J Hunter; J Silva; J S Haskill; R Snyderman
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E.

Authors:  D T Harris; G J Cianciolo; R Snyderman; S Argov; H S Koren
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

View more
  12 in total

1.  Sequence variation of human endogenous retrovirus ERV9-related elements in an env region corresponding to an immunosuppressive peptide: transcription in normal and neoplastic cells.

Authors:  M Lindeskog; P Medstrand; J Blomberg
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

2.  Tumor cells expressing a retroviral envelope escape immune rejection in vivo.

Authors:  M Mangeney; T Heidmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

3.  Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer.

Authors:  P J Simons; R A Oostendorp; M P Tas; H A Drexhage
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

4.  Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein.

Authors:  S Haraguchi; R A Good; M James-Yarish; G J Cianciolo; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 5.  A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways.

Authors:  Soichi Haraguchi; Robert A Good; Noorbibi K Day-Good
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Immunotherapy with monoclonal antibodies directed against the immunosuppressive domain of p15E inhibits tumour growth.

Authors:  M S Lang; E Hovenkamp; H F Savelkoul; P Knegt; W Van Ewijk
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

7.  Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide.

Authors:  M Nelson; D Nelson
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association.

Authors:  B A Brody; E Hunter
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer.

Authors:  Jonas Blomberg; Ali Sheikholvaezin; Amal Elfaitouri; Fredrik Blomberg; Anna Sjösten; Johan Mattson Ulfstedt; Rüdiger Pipkorn; Clas Källander; Christina Ohrmalm; Göran Sperber
Journal:  Adv Virol       Date:  2011-09-04

10.  Anti-inflammatory and vasoprotective activity of a retroviral-derived peptide, homologous to human endogenous retroviruses: endothelial cell effects.

Authors:  George J Cianciolo; Salvatore V Pizzo
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.